...which Affymetrix Inc. (NASDAQ:AFFX) acquired in 2008 for about $73 million; and cancer company Miikana Therapeutics Inc....

...triggered a $2 million milestone payment, paid in EntreMed stock to the former shareholders of Miikana...

...a $2 million milestone payment payable in cash or stock to the former stockholders of Miikana...

...recommended continuation of the study without any modifications. ENMD gained MKC-1 through its acquisition of Miikana Therapeutics Inc....

...study without any modifications. ENMD gained the oral cell cycle inhibitor through its acquisition of Miikana...

...to 60 patients advanced or metastatic breast cancer. ENMD gained MKC-1 through its acquisition of Miikana Therapeutics Inc....

...seek FDA approval for their products this year. Buy & raise When EntreMed (ENMD) acquired Miikana...
...with most of the proceeds earmarked for clinical development. "Between our own pipeline and the Miikana...
...Phase II cancer trials of Panzem and MKC-1 , that latter of which came from Miikana...

...Phase II trial in patients with oral MKC-1. ENMD got MKC-1 through its acquisition of Miikana Therapeutics Inc....

...ENMD completed its previously announced acquisition of Miikana for 10 million shares (see BioCentury, Jan. 2...
...$2.37 on Jan. 12, the day the deal closed, Miikana is valued at $23.7 million. Miikana...
...in milestones, payable in cash or stock at ENMD's option. EntreMed Inc. (ENMD), Rockville, Md. Miikana Therapeutics Inc....

...Cancer and inflammation company ENMD will acquire Miikana for 10 million shares, which values Miikana at...
...using ENMD's close of $2.13 on Dec. 21, the day before the deal was announced. Miikana...
...in cash or stock at ENMD's option. The deal is expected to close this month. Miikana's...